Cited by 574Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Open access
Yanamandra, Kiran, Kfoury, Najla, Jiang, Hong, Mahan, Thomas E., Ma, Shengmei, Maloney, Susan E., Wozniak, David F., Diamond, Marc I. +1 more·2013·Neuron

Abstract

Tau aggregation occurs in neurodegenerative diseases including Alzheimer's disease and many other disorders collectively termed tauopathies. trans-cellular propagation of tau pathology, mediated by extracellular tau aggregates, may underlie pathogenesis of these conditions. P301S tau transgenic mice express mutant human tau protein and develop progressive tau pathology. Using a cell-based biosensor assay, we screened anti-tau monoclonal antibodies for their ability to block seeding activity present in P301S brain lysates. We infused three effective antibodies or controls into the lateral ventricle of P301S mice for 3 months. The antibodies markedly reduced hyperphosphorylated, aggregated, and insoluble tau. They also blocked development of tau seeding activity detected in brain lysates using the biosensor assay, reduced microglial activation, and improved cognitive deficits. These data imply a central role for extracellular tau aggregates in the development of pathology. They also suggest that immunotherapy specifically designed to block trans-cellular aggregate propagation will be a productive treatment strategy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2013.07.046

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Immunotherapies targeting extracellular tau reduce pathology in mice.

    “Finally, immunotherapies targeting extracellular tau reduce pathology in mice (Yanamandra et al., 2013).”

    From Spontaneous pathology in PS19 tauopathy mice progresses via brain networks (2025) · cites this paper as Yanamandra et al., 2013

  • Human tau expression was consistently present across brain sections spanning the rostrocaudal extent of the hippocampus at 3, 6, 9 and 12 months of age in PS19 mice.

    “Staining for human tau (with HJ8.5 antibody (Yanamandra et al., 2013, Holmes et al., 2014)) showed consistent expression of human tau across brain sections spanning the rostrocaudal extent of the hippocampus at 3, 6, 9 and 12 months of age (Fig. 3).”

    From Spontaneous pathology in PS19 tauopathy mice progresses via brain networks (2025) · cites this paper as Yanamandra et al., 2013

  • Antibodies that block tau seeding activity can prevent the formation of tangles and brain atrophy in mice.

    “Alternatively, it has been shown that antibodies that block tau seeding activity can prevent the formation of tangles and brain atrophy in mice [183].”

    From Glial contributions to neurodegeneration in tauopathies (2017) · cites this paper as [183]

  • HJ8.5 in PS19 mice reduced tau seeding, hyperphosphorylation, thioflavin S staining, detergent-insoluble tau, brain atrophy, and cognitive deficits when given before significant tau pathology, whether intraventricularly or peripherally.

    “In preclinical studies, mouse anti-human tau monoclonal antibody HJ8.5 demonstrated reduced tau seeding, hyperphosphorylation and thioflavin S staining, reduced levels of detergent insoluble tau, and reduced brain atrophy and cognitive deficits in PS19 (P301S) mice, whether administered via intraventricular infusion (Yanamandra et al., 2013) or peripherally (Yanamandra et al., 2015) when administ”

    From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Yanamandra et al., 2013

  • Monoclonal antibodies against the amino-terminal or repeat domain (306-320) region, oligomeric tau, misfolded tau, pSer202, pThr231, pSer409, pSer413 and pSer422 have proved to be efficacious in tauopathy models.

    “In addition, monoclonal antibodies against the amino-terminal or repeat domain (306–320) region209–215, oligomeric tau216,217, misfolded tau201,218,219, pSer202220,221, pThr231208 pSer409222, pSer413223 and pSer422224 have proved to be efficacious in tauopathy models.”

    From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [213]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M.
Affiliations
Washington University in St. Louis (US)
Corresponding author
  • Diamond, Marc I.
  • Holtzman, David M.
Venue
Neuron
Publisher
Elsevier BV
Published
2013-10
Volume
80
Issue
2
Pages
402-414
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2059809766
Cited by
574
References
58
Citations by year
2026: 14 · 2025: 23 · 2024: 43 · 2023: 31 · 2022: 40 · 2021: 37 · 2020: 54 · 2019: 56 · 2018: 69 · 2017: 63 · 2016: 41 · 2015: 41 · 2014: 57 · 2013: 5
FWCI
33.42
Type
journal article
Language
en
Update notices
erratum (2013-12-18)
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Neurological Disorders and Stroke (R01NS071835)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
anti-tau antibodies, tau aggregation, tau seeding, P301S tau transgenic mice, tauopathy, Alzheimer's disease, immunotherapy, microglial activation, cognitive impairment, hyperphosphorylated tau
MeSH terms
Animals, Antibodies, Monoclonal, Brain, Cells, Cultured, Cognition Disorders, Humans, Mice, Transgenic, tau Proteins, Microglia, Tauopathies, Mice, Infusions, Intraventricular

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review